German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...

Buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel AG, people ...

Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE ...

Taking a closer look at the numbers, Stada’s specialty pharma arm grew sales 14% to 417.3 million euros ($464 million) during the first half of 2024. Stada credited the specialty pharma growth ...

Chicago-based buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel ...

(RTTNews) - Genpact Ltd. (G), an IT company, and Stada Arzneimittel AG (STDAY.PK, STDAF.PK), a maker of consumer healthcare, generic, and specialty pharma medicines, announced on Thursday that ...

Genpact Ltd. (G), an IT company, and Stada Arzneimittel AG (STDAY.PK, STDAF.PK), a maker of consumer healthcare, generic, and ...

Buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel AG, people with knowledge of the matter said. GTCR is seeking to hammer out terms of ...

Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE: G), a ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, and STADA (SAZ.DE), a leading manufacturer of ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...